Download Files:
Grazoprevir
$119 – $858
Products Details
Product Description
– Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively[1][2]. Grazoprevir inhibits SARS-CoV-2 3CLpro activity[3].
Web ID
– HY-15298
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C38H50N6O9S
Citations
– Antivir Res. 2019 Nov;171:104612.|Antiviral Res. 2017 Mar;139:18-24. |Antiviral Res. 2021 Dec 2;105224.|bioRxiv. 2023 Feb 27.|bioRxiv. 2023 Oct 26.|Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5.|Cancer Immunol Res. 2021 Jun 30.|Elife. 2020 Jun 9;9:e56469.|J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:15-24. |J Gastroenterol. 2019 May;54(5):449-458. |J Pharmaceut Biomed. 2020 Jan 30;178:112964.|Nat Biotechnol. 2019 Oct;37(10):1209-1216.|Nat Commun. 2020 Sep 4;11(1):4417.|Nat Methods. 2018 Jul;15(7):519-522.|Patent. US20180346589A1.|Patent. US20190010245A1.|Patent. US20220025003A1.|Pharmaceuticals. 2022 Feb 18;15(2):242.|Sci Rep. 2022 Jul 16;12(1):12197.|Sci Rep. 2019 Apr 5;9(1):5722.|Signal Transduct Target Ther. 2021 May 29;6(1):212.|Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5.
References
– [1]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.|[2]Summa V, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7.|[3]Harper S, et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med Chem Lett. 2012 Mar 2;3(4):332-6.
CAS Number
– 1350514-68-9
Molecular Weight
– 766.90
Compound Purity
– 99.99
SMILES
– COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC4=O)C(O[C@H]5CN(C([C@H](C(C)(C)C)N4)=O)[C@H](C(N[C@@]([C@@H]6C=C)(C6)C(NS(C7CC7)(=O)=O)=O)=O)C5)=N2)C=C1
Clinical Information
– Launched
Research Area
– Infection
Solubility
– DMSO : 50 mg/mL (ultrasonic)|Ethanol : 66.67 mg/mL (ultrasonic)
Target
– HCV;HCV Protease;SARS-CoV
Pathway
– Anti-infection;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
